Motesanib
Motesanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target vascular endothelial growth factor receptor 3 and vascular endothelial growth factor receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | 2 | — | — | 5 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 2 | 1 | — | — | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 2 | 1 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 1 | — | — | — | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | — | — | — | 5 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 4 | 1 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 3 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | 1 | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 1 | — | — | — | 2 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
| Paraneoplastic syndromes | D010257 | — | — | — | 1 | — | — | — | 1 |
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 3 | — | — | — | — | 3 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 2 | — | — | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Motesanib |
| INN | motesanib |
| Description | Motesanib is a pyridinecarboxamide. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21 |
Identifiers
| PDB | — |
| CAS-ID | 453562-69-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL572881 |
| ChEBI ID | 51098 |
| PubChem CID | 11667893 |
| DrugBank | — |
| UNII ID | U1JK633AYI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FLT1
FLT1
Organism
Homo sapiens
Gene name
FLT1
Gene synonyms
FLT, FRT, VEGFR1
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 1
Protein synonyms
FLT, FLT-1, fms related tyrosine kinase 1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor
Uniprot ID
Mouse ortholog
Flt1 (14254)
vascular endothelial growth factor receptor 1 (P35969)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 892 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use